Group 1 - RuiLian New Materials reported a total operating revenue of 1.677 billion yuan for 2025, an increase of 14.95% year-on-year, with a net profit of 311 million yuan, up 23.48% year-on-year [1] - China Shenhua's subsidiary, Guoneng Qingyuan Power, successfully put its fourth generator unit into commercial operation, expected to provide approximately 20 billion kWh of clean energy annually [2] - Qijiang Airlines announced a 6.04% year-on-year decline in passenger turnover for January 2026, with a passenger load factor of 84.03%, up 1.61% year-on-year [3] Group 2 - QiZheng Tibetan Medicine reported a total operating revenue of 2.416 billion yuan for 2025, a year-on-year increase of 3.34%, with a net profit of 646 million yuan, up 10.98% year-on-year [5] - QiaoYin Co. announced the termination of its artificial intelligence industry headquarters project due to changes in investment cooperation conditions [6] - New Point Software plans to use 90.81 million yuan of surplus raised funds for new projects, including AI-driven software development [7] Group 3 - High Measurement Co. announced plans for major shareholders and executives to reduce their holdings by up to 3.19% of the company's shares [8] - SAIC Group's subsidiary plans to establish a private equity fund with an initial scale of 2.5 billion yuan, focusing on solid-state batteries and chip localization [9] - Tianqi Lithium announced the resignation of its deputy general manager due to personal career planning [10] Group 4 - ZhongKong Technology reported a total operating revenue of 8.051 billion yuan for 2025, a decrease of 11.90%, with a net profit of 450 million yuan, down 59.70% year-on-year [11] - Spring Airlines reported a 6.28% year-on-year increase in total passenger volume for January 2026, with a total available ton-kilometers of 57,008.37 [12] - Qifan Cable's controlling shareholder reduced its stake by 3% through various trading methods [13] Group 5 - China Chemical signed contracts worth a total of 36.925 billion yuan in January 2026, with significant contracts exceeding 5 billion yuan totaling 11.371 billion yuan [19] - SaiTuo Bio received a CEP certificate for its raw material drug Betamethasone, which is used to treat allergies and autoimmune inflammation [20] - Giant Star Agriculture reported a sales revenue of 649 million yuan from commodity fat pigs in January 2026, with a sales volume of 404,400 pigs [23] Group 6 - Qinglong Pipe Industry's subsidiary won a 146 million yuan pipeline project [24] - Changshan Pharmaceutical announced that some of its products are expected to be selected for national centralized procurement [26] - Yangdian Technology completed the transfer of 12.96% of its shares through an agreement [27] Group 7 - Deepin Technology's investment fund introduced new limited partners and adjusted the capital contributions of some partners [28] - Qingyun Technology plans to pledge 25% of its shares for a loan application of up to 30 million yuan [29] - LaiMei Pharmaceutical reported a 57.20% year-on-year decline in net profit for 2025 [30] Group 8 - YouLiDe reported a 16.88% year-on-year decline in net profit for 2025, with total operating revenue of 1.221 billion yuan, up 7.99% [31] - Warner Pharmaceutical reported a net profit of 241 million yuan for 2025, an increase of 46.95% year-on-year [32] - LianRui New Materials reported a net profit of 293 million yuan for 2025, an increase of 16.42% year-on-year [33] Group 9 - HuaQin Technology expects a 24.28% year-on-year decrease in net profit for 2025, with projected revenue of 1.251 billion yuan, up 9.83% [34] - QiPai Technology's shareholder subscribed for 6.3 million shares, accounting for 5.49% of the total share capital [35] - Qilin Security's shareholders completed their planned share reductions without exceeding the original plan [36] Group 10 - Dameng Data announced the lifting of the detention of its senior vice president, allowing him to resume his duties [37] - Haiyou Engineering won a contract for the "NFPS COMP5" project worth approximately 4 billion USD, with the company's share exceeding 800 million USD [38] - Yatai Group plans to sell 20.81% of its shares in Northeast Securities, pending confirmation of financial statements [39]

公司取得倍他米松原料药CEP证书，标志着公司该原料药可以在认可CEP证书的国际市场进行销售，将 为公司倍他米松原料药拓展国际市场带来积极的影响，进一步丰富公司的产品线，有利于提升公司在化 学原料药领域的市场竞争力。 赛托生物（300583）(300583.SZ)发布公告，公司控股子公司山东斯瑞药业有限公司(以下简称"斯瑞药 业")近日收到欧洲药品质量管理局(以下简称"EDQM")签发的原料药欧洲药典适用性证书(以下简称"CEP 证书")。涉及化学原料药名称："BETAMETHASONE倍他米松"。 ...

公司取得倍他米松原料药CEP证书，标志着公司该原料药可以在认可CEP 证书的国际市场进行销售，将 为公司倍他米松原料药拓展国际市场带来积极的影响，进一步丰富公司的产品线，有利于提升公司在化 学原料药领域的市场竞争力。 智通财经APP讯，赛托生物(300583.SZ)发布公告，公司控股子公司山东斯瑞药业有限公司(以下简称"斯 瑞药业")近日收到欧洲药品质量管理局(以下简称"EDQM")签发的原料药欧洲药典适用性证书(以下简 称"CEP证书")。涉及化学原料药名称："BETAMETHASONE 倍他米松"。 ...

化学原料药名称：BETAMETHASONE 倍他米松 药品生产商/持有人：山东斯瑞药业有限公司 生产地址：山东省菏泽市定陶区东外环路南段 证书编号：CEP 2024-446-Rev 00 发证机关：欧洲药品质量管理局（EDQM） 有效期：自 2026 年 2 月 11 日起五年内有效 二、原料药的相关情况 倍他米松是一种主要用于治疗过敏和自身免疫性炎症的激素类药物，能够帮 助身体减轻炎症反应，防止组织因过度炎症受损，同时抑制免疫系统过度反应和 过敏现象。 公司于 2024 年 9 月向 EDQM 提交了倍他米松（原料药）的 CEP 申请。EDQM 官网显示，除斯瑞药业外，全球倍他米松原料药生产企业中有 7 家持有有效的 CEP 证书。根据 IQVIA 数据统计，倍他米松原料药 2024 年全球需求量近 2 吨。 证券代码：300583 证券简称：赛托生物 公告编号：2026-007 山东赛托生物科技股份有限公司 关于子公司收到化学原料药欧洲CEP证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公 ...

证券代码：300583 证券简称：赛托生物 公告编号：2026-006 山东赛托生物科技股份有限公司 关于公司及子公司重大诉讼的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 重要内容提示： 1、案件所处的诉讼阶段：法院已立案受理，尚未正式开庭审理。 2、上市公司所处的当事人地位：山东赛托生物科技股份有限公司（以下简 称"公司"）及控股子公司山东斯瑞药业有限公司（以下简称"斯瑞药业"）为 被告一、被告二。 3、涉案的金额：原告起诉状诉讼请求的金额为 22,600 万元人民币，此金额 包含原告根据斯瑞药业公开环评报告信息计算利得 22,560 万元和其他费用 40 万元。该涉案金额仅为原告起诉状所载诉讼请求的金额，不代表法院最终审理结 果。 4、对上市公司损益产生的影响：公司产品均为自主研发，公司对原告主张 不予认可，并将积极应诉。公司为甾体药物龙头企业，并实现了"甾体药物核心 原料-中间体-高端中间体-原料药-制剂"一体化产业布局，产品品类较多，本次 专利诉讼仅涉及一款中间体产品，其占公司主营业务收入比例较低。本次诉讼尚 未开庭审理，后续判决结果存在不确 ...

Group 1 - The core focus of the company is on business development and qualification certification, particularly in high-end respiratory active pharmaceutical ingredients [1] - The company has a strategy to adjust pricing based on market conditions to expand channels and increase market share [1] - The subsidiary, Sry Pharmaceutical, has received a high-tech enterprise certificate valid for three years, indicating the company's strengthening in innovation and technology capabilities [1] Group 2 - The stock price of the company has shown fluctuations over the past week, ranging from 14.81 yuan to 14.99 yuan, with a total change of 1.35% and a volatility of 3.72% [2] - Trading volume and turnover rate have remained active, with a single-day increase of 1.69% on February 9, followed by a decrease of 0.66% on February 11 [2] - The current stock price is close to the 20-day moving average, indicating some short-term pressure in the technical analysis [2] Group 3 - Institutional interest in the company is moderate, with a neutral sentiment prevailing in public opinion [3] - Two institutions have provided profit forecasts, expecting a net profit growth of 29.12% in 2025 and 17.67% in 2026, suggesting continued revenue expansion [3] - Institutional ratings are neutral with no clear target price, and the low proportion of institutional holdings reflects market caution regarding the company's short-term outlook [3]

（文章来源：证券日报） 证券日报网讯 2月6日，赛托生物发布公告称，公司控股子公司山东斯瑞药业有限公司再次通过高新技 术企业认定，取得由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、国家税务总局山东省 税务局联合颁发的高新技术企业证书，有效期三年，自2025年起连续三年按15%税率缴纳企业所得税。 ...

格隆汇2月6日丨赛托生物(300583.SZ)公布，公司控股子公司山东斯瑞药业有限公司（简称"斯瑞药业"） 已通过高新技术企业审查并于近日取得由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、 国家税务总局山东省税务局联合颁发的高新技术企业证书原件，发证时间：2025年12月8日，证书编号 为：GR202537002998，有效期三年。 ...

格隆汇2月6日丨赛托生物(300583.SZ)公布，公司控股子公司山东斯瑞药业有限公司（简称"斯瑞药业"） 已通过高新技术企业审查并于近日取得由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、 国家税务总局山东省税务局联合颁发的高新技术企业证书原件，发证时间：2025年12月8日，证书编号 为：GR202537002998，有效期三年。 ...

证券代码：300583 证券简称：赛托生物 公告编号：2026-005 山东赛托生物科技股份有限公司 关于控股子公司再次获得高新技术企业证书的公告 山东赛托生物科技股份有限公司 二〇二六年二月六日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导 性陈述或重大遗漏。 山东赛托生物科技股份有限公司（以下简称"公司"）控股子公司山东斯瑞 药业有限公司（以下简称"斯瑞药业"）已通过高新技术企业审查并于近日取得 由山东省科学技术厅、山东省工业和信息化厅、山东省财政厅、国家税务总局山 东省税务局联合颁发的高新技术企业证书原件，发证时间：2025 年 12 月 8 日， 证书编号为：GR202537002998，有效期三年。 根据《中华人民共和国企业所得税法》以及国家对高新技术企业的相关税收 规定，斯瑞药业自通过高新技术企业认定的当年起三年内享受国家关于高新技术 企业的相关税收优惠政策，按 15%的税率缴纳企业所得税。此次高新技术企业证 书的重新认定，是对其技术实力及研发水平的肯定，对公司的经营发展产生积极 影响。 特此公告。 董事会 ...